A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT ID: NCT02810951

Last Updated: 2023-02-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-01
• Study Completion Date: 2022-04-18

Brief Summary

The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD

Detailed Description

RDEB is a rare skin and connective tissue disease characterized clinically by skin fragility with easy blistering, erosion and scarring of skin and mucous membranes, and caused by the deficiency of the protein type VII collagen (COL7). The objective of this study is evaluate the safety of FCX-007 intradermal injections in RDEB subjects. Additionally, the trial will evaluate COL7 expression, the presence of anchoring fibrils, as well evidence of wound healing.

Approximately twelve subjects are expected to enroll in the Phase I/II trial. Phase I will enroll approximately six adult subjects. Phase II will enroll approximately six subjects both adults and pediatric (aged seven (7) years or older). All subjects will receive FCX-007 to one or more paired target RDEB wounds. Proof of mechanism will be monitored through digital photography of target wounds and assays conducted on biopsies taken from intact skin sites where FCX-007 is administered.

Conditions

Epidermolysis Bullosa Dystrophica, Recessive

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FCX-007

In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.

In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.

All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.

One wound in each target wound pair will be used as control for efficacy and safety evaluations.

Group Type: EXPERIMENTAL

FCX-007

Intervention Type: GENETIC

FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.

Interventions

FCX-007

FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.

Intervention Type: GENETIC

Other Intervention Names

Genetically-Modified Autologous Human Dermal Fibroblasts

Eligibility Criteria

Inclusion Criteria

1. Age

1. Phase I: Eighteen (18) years or older.

2. Phase II: Seven (7) years or older.

2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)

Exclusion Criteria

1. Medical instability limiting ability to travel to the investigative center.

2. Active infection with HIV, hepatitis B or hepatitis C or evidence of other systemic infection

3. Current evidence of metastatic squamous cell carcinoma at the site to be injected

4. Clinically significant abnormal laboratory result or other significant clinical abnormalities

5. Receipt of a chemical or biological study product for the specific treatment of RDEB in the past six months

• Minimum Eligible Age: 7 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Castle Creek Biosciences, LLC.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Stanford University

Stanford, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

FD-R-6113-01

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

FI-EB-001

Identifier Type: -

Identifier Source: org_study_id